Researchers have proposed an efficient feature search approach for estimating the state of health of lithium-ion batteries, aiming to reduce the reliance on manually selected aging features. The method uses Bayesian optimization to search multidimensional feature spaces and then applies an ensemble regression model to improve the accuracy and robustness of battery health estimation.

Researchers have developed an economical vehicle-side strategy for electric bus charging stations participating in vehicle-to-grid services, using reinforcement learning to optimize when and how long buses provide grid support. The study focuses on a real electric bus charging station in China?s Pearl River Delta region and evaluates how health-aware vehicle-to-grid operation can reduce lifecycle cost while extending battery life.

Semaglutide, the active ingredient in GLP-1 weight loss drugs, directly improves liver function through a specific subset of liver cells called liver sinusoidal endothelial cells (LSECs), independently of any weight loss. Contrary to the long-held assumption that liver cells lack the receptor semaglutide binds to, the study found that LSECs do carry this receptor, and when activated, they release anti-inflammatory molecules that calm the broader liver environment, reducing inflammation and scarring associated with metabolic liver disease (MASH). The findings suggest that physicians may be able to prescribe lower doses of GLP-1 medicines to treat liver disease — avoiding the side effects and costs of higher doses needed for significant weight loss — and that liver health, not just weight, should be a key measure of treatment success.

A research paper by scientists at Gongli Hospital of Pudong New Area presented developed a sonodynamic nanoplatform that simultaneously eradicates primary breast tumors via ferroptosis and apoptosis and blocks their spread to bone tissues.

The research paper, published on Mar 23, 2026 in the journal Cyborg and Bionic Systems.

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30%. Chemotherapy alone suffers from off‑target toxicity and drug resistance. Immunotherapy offers precision and durable effects but shows limited efficacy as monotherapy. Combining chemotherapy with immunotherapy is emerging as a promising paradigm. This review summarizes the rationale and advances of combining immune checkpoint inhibitors, CAR‑T, CAR‑NK, CAR‑macrophage therapies, antibody‑drug conjugates, bispecific antibodies, and cancer vaccines with chemotherapy for AML. We discuss preclinical and clinical progress, core challenges (off‑target toxicity, tumor heterogeneity, variable efficacy), and future directions toward precision medicine.